The 11th China (Taizhou) International Medical Expo saw the signing of cooperation agreement for 24 projects on September 20, which involved a total investment of 19.755 billion yuan ($2.91 billion), in China Medical City, the Taizhou-based life science incubator.

Taizhou also announced 25 preferential measures at the meeting to help pharmaceutical companies conducting clinical trials of new drugs.

File photo/CFP

More support will be provided to seven concentrations, such as the innovative development of drugs, medical devices, foods for special medical purpose and dietary supplement, scaling a business, building an innovation-friendly system, developing health care industry, and attracting investment. These measures cover all stages of the pharmaceutical industry, from research and development to production, sales and application.

DDSome, a company specialized in the development and commercialization of injections, signed an agreement to move its headquarters from Shanghai to China Medical City. The company's general manager Mao Wenxue said that he has personally witnessed the rapid rise of China Medical City in over ten years, so he chose to locate the new headquarters in the medical high-tech zone.

Zhang Xiaobing, member of the Standing Committee of the CPC Taizhou Committee and secretary of the Party Working Committee of the medical high-tech Zone, said that he hopes that these measures will enhance the sense of gain for business leaders and further drive growth in the area as a pharmaceutical powerhouse.

Contact us at english@jschina.com.cn